Keyway TCR-like Antibody (TCR mimic) Discovery: Fully Integrated Workflow to Get from Target Idea to Highly Specific & Functional Lead Candidate
Time: 8:55 am
day: Conference Day One
Details:
• TCR-like antibody therapeutics (TCR mimics) enable the targeting of intracellular proteins
(>70% of the human proteome) that have not been addressed by conventional cancer immunotherapies while avoiding the manufacturing and regulatory challenges of other TCRbased modalities.
• Keyway TCRm Discovery is the industry leading service to deliver fully functional and highlyspecific lead TCRm candidates by integrating high quality pMHC generation, best-in-class antibody discovery capabilities, comprehensive AI/ML enabled specificity screening, and therapeutically-tailored functional testing.
• Keyway TCRm Discovery is led by pioneering minds in the field of TCR-based therapies and the team has successfully executed 9+ partner projects across a variety of targets and pHLA.
